These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22153719)

  • 21. The molecular rationale of Src inhibition in colorectal carcinomas.
    Gargalionis AN; Karamouzis MV; Papavassiliou AG
    Int J Cancer; 2014 May; 134(9):2019-29. PubMed ID: 23733480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of Src family kinases and therapeutic implications of their modulators.
    Kumar A; Jaggi AS; Singh N
    Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SRC: a century of science brought to the clinic.
    Aleshin A; Finn RS
    Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Src in breast cancer.
    Finn RS
    Ann Oncol; 2008 Aug; 19(8):1379-1386. PubMed ID: 18487549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dasatinib: an anti-tumour agent via Src inhibition.
    Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
    Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
    Klener P; Klener P
    Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
    Gomes EG; Connelly SF; Summy JM
    Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Src as a therapeutic target in men with prostate cancer and bone metastases.
    Saad F
    BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
    Rucci N; Susa M; Teti A
    Anticancer Agents Med Chem; 2008 Apr; 8(3):342-9. PubMed ID: 18393792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Src continues aging: current and future clinical directions.
    Kopetz S; Shah AN; Gallick GE
    Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
    Ortiz R; Díaz J; Díaz-Valdivia N; Martínez S; Simón L; Contreras P; Lobos-González L; Guerrero S; Leyton L; Quest AFG
    Biochem Pharmacol; 2020 Jul; 177():113941. PubMed ID: 32240650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dasatinib in solid tumors.
    Kim LC; Rix U; Haura EB
    Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
    Benati D; Baldari CT
    Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
    Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
    Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
    Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
    Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
    Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.